Intrexon acquires mucosal therapeutics play ActoGeniX
Synthetic biology company Intrexon Corp. (NYSE:XON) will acquire ActoGeniX N.V. (Zwijnaarde, Belgium) for $60 million. Intrexon will gain ActoGeniX's TopAct platform, an oral delivery technology based on living, non-pathogenic microorganisms, and a pipeline including two clinical candidates.
ActoGenix's AG013, an ActoBiotic genetically modified to express and secrete human trefoil factor 3 ( TFF3), is in Phase II testing for oral mucositis and stomatitis. AG014, a Lactococcus lactis ActoBiotic genetically modified to express and secrete an anti-tumor necrosis factor (TNF) alpha antibody, is in Phase I to treat inflammatory bowel disease. ActoBiotics are whole bacteria engineered to produce therapeutic proteins or peptides in the patient's gut. ...